Compare HBT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBT | CGEM |
|---|---|---|
| Founded | 1920 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.3M | 780.4M |
| IPO Year | 2019 | 2020 |
| Metric | HBT | CGEM |
|---|---|---|
| Price | $27.58 | $15.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $28.63 | ★ $28.80 |
| AVG Volume (30 Days) | 23.0K | ★ 770.4K |
| Earning Date | 04-27-2026 | 03-30-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | ★ 9.18 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.40 | N/A |
| Revenue Next Year | $11.80 | N/A |
| P/E Ratio | $14.69 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.46 | $5.68 |
| 52 Week High | $29.88 | $16.74 |
| Indicator | HBT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 76.32 |
| Support Level | $24.39 | $6.75 |
| Resistance Level | $27.85 | N/A |
| Average True Range (ATR) | 0.87 | 1.02 |
| MACD | -0.22 | 0.30 |
| Stochastic Oscillator | 29.16 | 85.22 |
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.